<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047071</url>
  </required_header>
  <id_info>
    <org_study_id>PI13/00743</org_study_id>
    <nct_id>NCT02047071</nct_id>
  </id_info>
  <brief_title>Effect of CPAP Treatment in Women With Moderate-to-severe OSA.</brief_title>
  <official_title>Effect of Continuous Positive Airways Pressure (CPAP) in Women With Moderate-to-severe Obstructive Sleep Apnea (OSA). A Multicenter, Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francisco Campos-Rodriguez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sociedad Española de Neumología y Cirugía Torácica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Continuous Positive Airways Pressure (CPAP)
      improves quality of life, cardiovascular (blood pressure) and metabolic profile (glucose and
      lipid metabolism) in females with moderate-to-severe Obstructive Sleep Apnea (OSA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: multicenter, open-label, randomized, controlled trial of parallel groups with a
      final blind evaluation.

      Study sites. The following hospitals will participate in the study: Valme (Sevilla), la Fe
      (Valencia), Virgen del Rocío (Sevilla), Gral Yagüe (Burgos), San Pedro de Alcántara
      (Cáceres), Dr Peset (Valencia), Severo Ochoa (Madrid), Reina Sofía (Córdoba), Dr Negrín (Las
      Palmas de Gran Canaria), Virgen de la Victoria (Málaga), Río Hortega (Valladolid), Costa del
      Sol (Málaga), Marqués de Valdecilla (Santander), Albacete (Albacete), Virgen del Puerto
      (Cáceres), Puerta de Hierro (Madrid), Consorcio Sanitario de Terrassa (Barcelona), Getafe
      (Madrid), Gral de Alicante (Alicante), Morales Meseguer (Murcia), Tomelloso (Ciudad Real),
      and Fundación Jiménez Díaz (Madrid). All centers from Spain.

      Methods: consecutive outpatient women aged 18-75 years and referred to the sleep clinics for
      suspicion of OSA will be studied. They will undergo a diagnostic home respiratory polygraphy,
      and those diagnosed with moderate-to-severe OSA (AHI ≥15) will be eligible for this study and
      randomized to optimal CPAP treatment or conservative treatment for 12 weeks. Every women will
      fulfill a standardized protocol and different quality of life questionnaires. Office blood
      pressure will be measured. Fasting blood samples will be collected to assess glucose and
      lipid metabolism. All the measurements will be performed at baseline and after 12 weeks of
      follow-up. Women will be examined at the time of inclusion, after 4 weeks of follow-up and at
      the end of follow-up (12 weeks).

      149 women with moderate-to-severe OSA need to be enrolled in each study arm, according to the
      sample size calculated to achieve a clinically significant improvement in the Quebec Sleep
      Questionnaire. The results will be analyzed both on an intention-to-treat basis and on a
      per-protocol basis (data only from patients who finish the study and show good adherence to
      CPAP, defined as an average objective use of at least 4 hours/day).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in quality of life on the Quebec Sleep Questionnaire (QSQ) at week 12</measure>
    <time_frame>Baseline, 12 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life on the 12-Item Short Form Health Survey (SF-12) at week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mood state on the Abbreviated Profile Of Mood States (POMS) at week 12</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sleepiness on the Epworth Sleepiness Score (ESS) at week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anxiety and depression on the Hospital Anxiety and Depression questionnaire (HAD) at week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life on the Visual Analogic Scale (VAS) at week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sleep apnea symptoms at week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure at week 12</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in office blood pressure from baseline at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucose metabolism at week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lipid metabolism at week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants with CPAP use &gt;= 4 hours/day as a Measure of CPAP adherence</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conservative treatment. This group will be receive standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous positive airways pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous positive airways pressure</intervention_name>
    <description>Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.</description>
    <arm_group_label>Continuous positive airways pressure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate-to-severe OSA (Apnea-Hypopnea index ≥15) diagnosed by Home Respiratory
             Polygraphy.

          -  Age between 18-75 years.

        Exclusion Criteria:

          -  diagnosis of narcolepsy or restless legs syndrome

          -  unstable cardiovascular profile (cardiovascular event in the previous 3 months)

          -  cancer or life expectancy lower than 1 year

          -  uncontrolled psychiatric disorders

          -  central sleep apnea (&gt;50% of central events)

          -  pregnancy

          -  risky jobs and severe hypersomnolence (Epworth &gt;=18) requiring urgent treatment

          -  either respiratory failure (SaO2&lt;90% or partial oxygen pressure [pO2] &lt;60 mmHg or
             Long-term O2 therapy

          -  heart failure (New York Heart Association class III-IV)

          -  prior CPAP therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Campos-Rodriguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sociedad Española de Neumología y Cirugía Torácica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Valme</name>
      <address>
        <city>Seville</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2014</study_first_submitted>
  <study_first_submitted_qc>January 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sociedad Española de Neumología y Cirugía Torácica</investigator_affiliation>
    <investigator_full_name>Francisco Campos-Rodriguez</investigator_full_name>
    <investigator_title>Pneumology specialist</investigator_title>
  </responsible_party>
  <keyword>Obstructive sleep apnea</keyword>
  <keyword>Female gender</keyword>
  <keyword>Continuous Positive Airway Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

